WHAT IS CLAIMED IS:

1. An immunogenic chimeric influenza virus hemagglutinin (HA) polypeptide comprising

(a) an HA stem domain comprising an HA1 N-terminal stem segment and an HA1 C-terminal stem segment, wherein the HA1 N-terminal stem segment consists of amino acid residues $HA_{N\text{-}term}$ through A_p of the HA1 domain, and wherein the HA1 C-terminal stem segment consists of amino acid residues A_q through $HA_{C\text{-}term}$ of an HA1 domain, and

(b) an HA globular head domain comprising the amino acid residues between A_p and A_q of an HA1 domain,

wherein $HA_{N\text{-}term}$ is the N-terminal amino acid of a mature HA0 protein lacking a signal peptide, wherein $HA_{C\text{-}term}$ is the C-terminal amino acid of the HA1 domain, wherein A_p is Cys that corresponds to amino acid position 52 of HA1 from an H3 hemagglutinin, wherein A_q is Cys that corresponds to amino acid position 277 of HA1 from an H3 hemagglutinin, wherein the HA globular head domain is heterologous to the HA stem domain, wherein the HA stem domain comprises at least one modified glycosylation site, wherein the modified glycosylation site comprises a modification of a naturally occurring glycosylation site having an amino acid sequence Asn-Xaa-Ser/Thr/Cys, and wherein the modification disrupts the ability of a glycan to attach to the modified glycosylation site, and wherein Xaa is any amino acid.

2. The chimeric influenza virus HA polypeptide of claim 1, wherein the modification comprises one or more amino acid substitutions of the naturally occurring glycosylation site.

3. The chimeric influenza virus HA polypeptide of claim 1, wherein the modified glycosylation site is located at amino acid positions selected from the group consisting of amino acid positions 20-22 21-23, 33-35, 46-48, 289-291, 290-292, 296-298 and 481 483, according to the H3 numbering system, wherein the HA stem domain is an HA stem domain from an influenza virus of subtype H1, H2, H5, H6, H8, H9, H11, H12, H13, and H16.

4. The chimeric influenza virus HA polypeptide of claim 1, wherein the modified glycosylation site is located at amino acid positions selected from the group consisting of amino acid positions 8-10, 22-24, 38-40, 46-48, 296-298, 410-412, and 481-483, according

to the H3 numbering system, wherein the HA stem domain is an HA stem domain from an influenza virus of subtype H3, H4, H7, H10, H14, or H15.

5. The chimeric influenza virus HA polypeptide of any one of claims 1-4, wherein the HA globular head domain further comprises one or more non-naturally occurring glycosylation sites having an amino acid sequence Asn-Xaa-Ser/Thr/Cys, wherein Xaa is any amino acid.

6. The chimeric influenza virus hemagglutinin polypeptide of claim 5, wherein the HA globular head domain is the HA globular head domain of an influenza virus H1 subtype and wherein the non naturally occurring glycosylation site is located in an Sa, Sb, Ca, or Cb antigenic site; or wherein the HA globular head domain is an influenza virus H3 subtype and wherein the non naturally occurring glycosylation site is located in an A, B, C, or D antigenic site.

7. The chimeric influenza virus HA polypeptide of claim 6, wherein the non-naturally occurring glycosylation site is at hemagglutinin amino acid positions 59-61, 129-131, 158-160 or 165-167, according to H3 numbering.

8. The chimeric influenza virus HA polypeptide of any one of claims 1-8, wherein the HA stem domain is an HA stem domain of a seasonal influenza virus strain.

9. The chimeric influenza virus HA polypeptide of claim 1 or 8, wherein the HA stem domain is the HA stem domain of an influenza virus of subtype H1.

10. The chimeric influenza virus HA polypeptide of claim 1 or 8, wherein the HA stem domain is the HA stem domain of an influenza virus of subtype H3.

11. The chimeric influenza virus HA polypeptide of claim 9, wherein the HA globular head domain is the HA globular head domain of an influenza virus of subtype H4, H5, H6, H7, H8, H9, H10, H11, H12, H13, H14, H15, H16, or H17.

12. The chimeric influenza virus HA polypeptide of claim 10, wherein the HA globular head domain is the HA globular head domain of an influenza virus of subtype H4, H5, H6, H7, H8, H9, H10, H11, H12, H13, H14, H15, H16, or H17.

13. The chimeric influenza virus HA polypeptide of claim 11, wherein the HA globular head domain is the HA globular head domain of an influenza virus of subtype H5, H6, H8, H9, H11, H12, H13, or H16.

14. The chimeric influenza virus HA polypeptide of claim 12, wherein the HA globular head domain is the HA globular head domain of an influenza virus of subtype H4, H7, H10, H14, or H15.

15. The HA polypeptide of any one of claims 1-14, wherein said polypeptide is soluble.

16. The HA polypeptide of any one of claims 1-15, wherein said polypeptide further comprises a foldon or trimerization domain.

17. A nucleic acid encoding the polypeptide of any of claims 1 to 16.

18. An isolated host cell expressing the nucleic acid of claim 17.

19. The cell of claim 18, wherein the host cell is a mammalian cell or an insect cell.

20. A virus comprising a genome engineered to express the nucleic acid of claim 17.

21. A virus comprising the polypeptide of any one of claims 1 to 16.

22. The virus of claim 20, wherein the virus is an influenza virus.

23. The virus of claim 21, wherein the virus is an influenza virus.

24. The virus of claim 22, which is inactivated or split.

25. The virus of claim 23, which is inactivated or split.

26. A virus-like particle comprising the polypeptide of any one of claims 1 to 16.

27. An immunogenic composition comprising the polypeptide of any one of claims 1 to 16.

28. An immunogenic composition comprising more than one polypeptide of any one of claims 1 to 16.

29. An immunogenic composition comprising the virus of claim 20.

30. An immunogenic composition comprising the virus of claim 21.

31. An immunogenic composition comprising the virus of claim 22.

32. An immunogenic composition comprising the virus of claim 23.

33. An immunogenic composition comprising the virus-like particle of claim 26.

34. The immunogenic composition of any one of claims 27 or 28 further comprising an adjuvant.

35. The immunogenic composition of claim 24, wherein the adjuvant is an aluminum salt, aluminum hydroxide, aluminum phosphate, aluminum sulfate, 3 De-O-acylated monophosphoryl lipid A, MF59, AS03, AS04, polysorbate 80, an imidazopyridine compound, an imidazoquinoxaline compound, saponins, QS21, complete Freund's adjuvant, incomplete Freund's adjuvant, an oil in water emulsion, squalene, peanut oil, CpG.

36. Use of an immunogenic composition of claim 27, 28, 34, or 35 in the manufacture of a medicament for immunizing a subject.

37. Use of an immunogenic composition of claim 29 in the manufacture of a medicament for immunizing a subject.

38. Use of an immunogenic composition of claim 30 in the manufacture of a medicament for immunizing a subject.

39. Use of an immunogenic composition of claim 31 in the manufacture of a medicament for immunizing a subject.

40. Use of an immunogenic composition of claim 32 in the manufacture of a medicament for immunizing a subject.

41. Use of an immunogenic composition of claim 33 in the manufacture of a medicament for immunizing a subject.

42. The use of any one of claims 36 to 41, wherein the immunogenic composition is to be administered intramuscularly or intranasally to the subject.

43. The use of claim 36, wherein the subject is a human.

44. The use of claim 37, wherein the subject is a human.

45. The use of claim 38, wherein the subject is a human.

46. The use of claim 39, wherein the subject is a human.

47. The use of claim 40, wherein the subject is a human.

48. The use of claim 41, wherein the subject is a human.

49. The use of claim 42, wherein the subject is a human.

50. The immunogenic composition of any one of claims 27 to 35 for use in immunizing a subject.

51. The immunogenic composition of claim 50, wherein the subject is a human.

52. Use of an immunogenic composition of claim 27, 28, 34, or 35 in the manufacture of a medicament for preventing an influenza virus disease in a subject.

53. Use of an immunogenic composition of claim 29 in the manufacture of a medicament for preventing an influenza virus disease in a subject.

54. Use of an immunogenic composition of claim 30 in the manufacture of a medicament for preventing an influenza virus disease in a subject.

55. Use of an immunogenic composition of claim 31 in the manufacture of a medicament for preventing an influenza virus disease in a subject.

56. Use of an immunogenic composition of claim 32 in the manufacture of a medicament for preventing an influenza virus disease in a subject.

57. Use of an immunogenic composition of claim 33 in the manufacture of a medicament for preventing an influenza virus disease in a subject.

58. The use of any one of claims 52 to 57, wherein the immunogenic composition is to be administered intramuscularly or intranasally to the subject.

59. The use of claim 52, wherein the subject is a human.

60. The use of claim 53, wherein the subject is a human.

61. The use of claim 54, wherein the subject is a human.

62. The use of claim 55, wherein the subject is a human.

63. The use of claim 56, wherein the subject is a human.

64. The use of claim 57, wherein the subject is a human.

65. The use of claim 58, wherein the subject is a human.

66. The immunogenic compositions of any one of claims 27 to 35 for use in preventing an influenza virus disease in a subject.

67. The immunogenic composition of claim 66, wherein the subject is a human.

68. A method of producing a chimeric influenza virus HA polypeptide comprising: (a) culturing the cell of claim 18 or 19, and (b) isolating the polypeptide from the cell.

69. The immunogenic composition of any one of claims 1-16, wherein the immunogenic composition induces production of neutralizing antibodies that are cross-reactive among HA subtypes.

WHAT IS CLAIMED IS:

1. A chimeric influenza virus hemagglutinin (HA) polypeptide comprising an HA stem domain and an HA globular head domain, wherein the HA globular head domain is heterologous to the HA stem domain.

2. A chimeric influenza virus hemagglutinin (HA) polypeptide comprising an HA stem domain of a seasonal influenza virus strain and an HA globular head domain of a heterologous influenza virus strain.

3. The chimeric influenza virus HA polypeptide of claim 1 or 2, wherein the HA stem domain maintains the cysteine residues designated Ap and Aq in Figure 1.

4. The chimeric influenza virus HA polypeptide of claim 1 or 2, wherein the HA stem domain is the HA stem domain of an influenza virus of subtype H1.

5. The chimeric influenza virus HA polypeptide of claim 1 or 2, wherein the HA stem domain is the HA stem domain of an influenza virus of subtype H3.

6. The chimeric influenza virus HA polypeptide of claim 4, wherein the HA globular head domain is the HA globular head domain of an influenza virus of subtype H4, H5, H6, H7, H8, H9, H10, H11, H12, H13, H14, H15, H16, or H17.

7. The chimeric influenza virus HA polypeptide of claim 5, wherein the HA globular head domain is the HA globular head domain of an influenza virus of subtype H4, H5, H6, H7, H8, H9, H10, H11, H12, H13, H14, H15, H16, or H17.

8. The chimeric influenza virus HA polypeptide of claim 6, wherein the HA globular head domain is the HA globular head domain of an influenza virus of subtype H5, H6, H8, H9, H11, H12, H13, or H16.

9. The chimeric influenza virus HA polypeptide of claim 7, wherein the HA globular head domain is the HA globular head domain of an influenza virus of subtype H4, H7, H10, H14, or H15.

10. A nucleic acid encoding the polypeptide of any of claims 1 to 9.

11. A cell expressing the nucleic acid of claim 10.

12. A virus comprising a genome engineered to express the nucleic acid of claim 10.

13. A virus comprising the polypeptide of any one of claims 1 to 9.

14. The virus of claim 12, wherein the virus is an influenza virus.

15. The virus of claim 13, wherein the virus is an influenza virus.

16. The virus of claim 14, which is inactivated or split.

17. The virus of claim 15, which is inactivated or split.

18. A virus-like particle comprising the polypeptide of any one of claims 1 to 9.

19. An immunogenic composition comprising the polypeptide of any one of claims 1 to 9.

20. An immunogenic composition comprising the virus of claim 12.

21. An immunogenic composition comprising the virus of claim 13.

22. An immunogenic composition comprising the virus of claim 14.

23. An immunogenic composition comprising the virus of claim 15.

24. An immunogenic composition comprising the virus-like particle of claim 18.

25. Use of an immunogenic composition of claim 19 in the manufacture of a medicament for immunizing a subject.

26. Use of an immunogenic composition of claim 20 in the manufacture of a medicament for immunizing a subject.

27. Use of an immunogenic composition of claim 21 in the manufacture of a medicament for immunizing a subject.

28. Use of an immunogenic composition of claim 22 in the manufacture of a medicament for immunizing a subject.

29. Use of an immunogenic composition of claim 23 in the manufacture of a medicament for immunizing a subject.

30. Use of an immunogenic composition of claim 24 in the manufacture of a medicament for immunizing a subject.

31. The use of claim 25, wherein the subject is a human.

32. The use of claim 26, wherein the subject is a human.

33. The use of claim 27, wherein the subject is a human.

34. The use of claim 28, wherein the subject is a human.

35. The use of claim 29, wherein the subject is a human.

36. The use of claim 30, wherein the subject is a human.

37. The use of claim 25, wherein the immunogenic composition is to be administered intramuscularly or intranasally to the subject.

38. Use of an immunogenic composition of claim 25 in the manufacture of a medicament for preventing an influenza virus disease.

39. Use of an immunogenic composition of claim 25 in the manufacture of a medicament for treating an influenza virus infection or an influenza virus disease.

40. Use of an immunogenic composition of claim 25 in the manufacture of a medicament for preventing an influenza virus disease.

41. Use of an immunogenic composition of claim 25 in the manufacture of a medicament for preventing an influenza virus disease.

42. The use of claim 26, wherein the immunogenic composition is to be administered intramuscularly or intranasally to the subject.

43. Use of an immunogenic composition of claim 26 in the manufacture of a medicament for preventing an influenza virus disease.

44. Use of an immunogenic composition of claim 26 in the manufacture of a medicament for treating an influenza virus infection or an influenza virus disease.

45. Use of an immunogenic composition of claim 26 in the manufacture of a medicament for preventing an influenza virus disease.

46. Use of an immunogenic composition of claim 26 in the manufacture of a medicament for preventing an influenza virus disease.

47. Use of an influenza virus hemagglutinin polypeptide to which a subject is naive in the manufacture of a medicament for preventing an influenza virus disease or infection in the subject.

48. The use of claim 47, wherein the influenza virus hemagglutinin polypeptide is from an influenza virus of subtype H2, H4, H5, H6, H7, H8, H9, H10, H11, H12, H13, H14, H15, H16, and/or H17.

49. The use of claim 48, wherein a second influenza virus hemagglutinin polypeptide to which the subject is naive is to be administered to said subject, wherein the second influenza virus hemagglutinin polypeptide is from an influenza virus of subtype H2, H4, H5, H6, H7, H8, H9, H10, H11, H12, H13, H14, H15, H16, and/or H17, and wherein the influenza virus hemagglutinin polypeptides of the first and second administrations are from different influenza virus subtypes.

50. The use of claim 49, wherein a third influenza virus hemagglutinin polypeptide to which the subject is naive is to be administered to said subject, wherein the third influenza virus hemagglutinin polypeptide is from an influenza virus of subtype H2, H4, H5, H6, H7, H8, H9, H10, H11, H12, H13, H14, H15, H16, and/or H17, and wherein the influenza virus hemagglutinin polypeptides of the first, second, and third administrations are from different influenza virus subtypes.

51. Use of an influenza virus in the manufacture of a medicament for preventing an influenza virus disease or infection in a subject, wherein said influenza virus comprises a hemagglutinin polypeptide to which the subject is naive.

52. The use of claim 51, wherein the influenza virus hemagglutinin polypeptide is from an influenza virus of subtype H2, H4, H5, H6, H7, H8, H9, H10, H11, H12, H13, H14, H15, H16, and/or H17.

53. The use of claim 52, comprising administering to said subject a second influenza virus, wherein said second influenza virus comprises a hemagglutinin polypeptide to which the subject is naive; wherein the hemagglutinin polypeptide of the second influenza virus is from an influenza virus of subtype H2, H4, H5, H6, H7, H8, H9, H10, H11, H12, H13, H14, H15, H16, and/or H17; and wherein the influenza virus hemagglutinin polypeptides of the first and second administrations are from different influenza virus subtypes.

54. The use of claim 53, wherein a third influenza virus is to be administered to said subject, wherein said third influenza virus comprises a hemagglutinin polypeptide to which the subject is naive; wherein the hemagglutinin polypeptide of the third influenza virus is from an influenza virus of subtype H2, H4, H5, H6, H7, H8, H9, H10, H11, H12, H13,

H14, H15, H16, and/or H17; and wherein the influenza virus hemagglutinin polypeptides of the first, second, and third administrations are from different influenza virus subtypes.

55. A chimeric influenza virus hemagglutinin (HA) polypeptide comprising an HA stem domain and an HA globular head domain, wherein the HA globular head domain is heterologous to the HA stem domain, wherein the HA stem domain comprises at least one modified glycosylation site, wherein the modified glycosylation site comprises a modification of a naturally occurring glycosylation site having an amino acid sequence Asn-Xaa-Ser/Thr/Cys, and wherein the modification disrupts the ability of a glycan to attach to the modified glycosylation site, and wherein Xaa is any amino acid.

56. The chimeric influenza virus HA polypeptide of claim 55, wherein the modification comprises one or more amino acid substitutions of the naturally occurring glycosylation site.

57. The chimeric influenza virus HA polypeptide of claim 55, wherein the modified glycosylation site is located at amino acid positions selected from the group consisting of amino acid positions 20-22 21-23, 33-35, 46-48, 289-291, 290-292, 296-298 and 481 483, according to the H3 numbering system, wherein the HA stem domain is an HA stem domain from an influenza virus of subtype H1, H2, H5, H6, H8, H9, H11, H12, H13, and H16.

58. The chimeric influenza virus HA polypeptide of claim 55, wherein the modified glycosylation site is located at amino acid positions selected from the group consisting of amino acid positions 8-10, 22-24, 38-40, 46-48, 296-298, 410-412,and 481-483, according to the H3 numbering system, wherein the HA stem domain is an HA stem domain from an influenza virus of subtype H3, H4, H7, H10, H14, or H15.

59. The chimeric influenza virus HA polypeptide of any one of claims 55-58, wherein the HA globular head domain further comprises one or more non-naturally occurring glycosylation sites having an amino acid sequence Asn-Xaa-Ser/Thr/Cys, wherein Xaa is any amino acid.

60. The chimeric influenza virus hemagglutinin polypeptide of claim 59, wherein the HA globular head domain is the HA globular head domain of an influenza virus H1 subtype and wherein the non-naturally occurring glycosylation site is located in an Sa, Sb, Ca, or Cb antigenic site; or wherein the HA globular head domain is an influenza virus H3 subtype and wherein the non-naturally occurring glycosylation site is located in an A, B, C, or D antigenic site.

61. The chimeric influenza virus hemagglutinin (HA) polypeptide of claim 59, wherein the non-naturally occurring glycosylation site is at hemagglutinin amino acid positions 59-61, 129-131, 158-160 or 165-167, according to H3 numbering.

62. A chimeric influenza virus hemagglutinin (HA) polypeptide comprising an HA stem domain and an HA globular head domain, wherein the HA globular head domain is heterologous to the HA stem domain, and wherein the HA globular head domain comprises one or more non-naturally occurring glycosylation sites having an amino acid sequence Asn-Xaa-Ser/Thr/Cys, and wherein Xaa is any amino acid.

63. A non-chimeric influenza virus hemagglutinin (HA) polypeptide comprising an HA stem domain and an HA globular head domain, wherein the HA globular head domain is homologous to the HA stem domain, wherein the HA stem domain comprises one or more modified glycosylation sites, wherein the modified glycosylation site comprises a modification of a naturally occurring glycosylation site having an amino acid sequence Asn-Xaa-Ser/Thr/Cys, and wherein the modification disrupts the ability of a glycan to attach to the modified glycosylation site, wherein Xaa is any amino acid.

64. The non-chimeric influenza virus HA polypeptide of claim 63, wherein the HA globular head domain further comprises one or more non-naturally occurring glycosylation site having an amino acid sequence Asn-Xaa-Ser/Thr/Cys, wherein Xaa is any amino acid.

65. The non-chimeric influenza virus hemagglutinin polypeptide of claim 64, wherein the HA globular head domain is the HA globular head domain of an influenza virus H1 subtype and wherein the non-naturally occurring glycosylation site is located in an Sa, Sb, Ca, or Cb antigenic site; or wherein the HA globular head domain is an influenza virus H3

subtype and wherein the non-naturally occurring glycosylation site is located in an A, B, C, or D antigenic site.

66. The non-chimeric influenza virus hemagglutinin (HA) polypeptide of claim 64 or 65, wherein the non-naturally occurring glycosylation site is at hemagglutinin amino acid position 59-61, 81-83, 129-131, 143-145, 158-160 and/or 165-167, 170-172, 187-189, 193-195, 197-199, 208-210, according to H3 numbering.

67. An influenza virus hemagglutinin (HA) stem domain polypeptide comprising:

a. an influenza hemagglutinin HA1 domain that comprises an HA1 N-terminal stem segment covalently linked to a linker of 1 to 50 heterologous residues that is in turn covalently linked to an HA1 C-terminal short stem segment; said HA1 domain in tertiary or quaternary association with

b. an influenza hemagglutinin HA2 domain,

wherein the influenza virus HA stem domain polypeptide domain further comprises one or more modified glycosylation sites, wherein the modified glycosylation site comprises a modification of a naturally occurring glycosylation site having an amino acid sequence Asn-Xaa-Ser/Thr/Cys, where the modification disrupts the ability of a glycan to attach to the modified glycosylation site, and wherein Xaa is any amino acid.

68. An influenza virus hemagglutinin (HA) stem domain polypeptide comprising:

a. an influenza hemagglutinin HA1 domain that comprises an HA1 N-terminal long stem segment covalently linked to a linker of 1 to 50 heterologous residues that is in turn covalently linked to an HA1 C-terminal long stem segment; said HA1 domain in tertiary or quaternary association with

b. an influenza hemagglutinin HA2 domain,

wherein the influenza virus HA stem domain polypeptide domain further comprises one or more modified glycosylation site, wherein the modified glycosylation site comprises a modification of a naturally occurring glycosylation site having an amino acid sequence Asn-Xaa-Ser/Thr/Cys, where the modification disrupts the ability of a glycan to attach to the modified glycosylation site, and wherein Xaa is any amino acid.

69. An influenza virus hemagglutinin (HA) stem domain polypeptide comprising:

a. an influenza hemagglutinin HA1 domain that comprises an HA1 N-terminal stem segment covalently linked to a linker of 1 to 50 heterologous residues that is in turn covalently linked to an HA1 C-terminal stem segment; said HA1 domain in tertiary or quaternary association with

b. an influenza hemagglutinin HA2 domain,

wherein the influenza virus HA stem domain polypeptide domain further comprises one or more modified glycosylation site, wherein the modified glycosylation site comprises a modification of a naturally occurring glycosylation site having an amino acid sequence Asn-Xaa-Ser/Thr/Cys, where the modification disrupts the ability of a glycan to attach to the modified glycosylation site, and wherein Xaa is any amino acid.

70. An influenza virus hemagglutinin (HA) stem domain polypeptide comprising:

a. an influenza hemagglutinin HA1 domain that comprises, linked in the following order: an HA1 N-terminal stem segment, a first linker of 1 to 50 heterologous residues, an HA1 intermediate stem segment, a second linker of 1 to 50 heterologous residues and an HA1 C-terminal stem segment; said HA1 domain in tertiary or quaternary association with

b. an influenza hemagglutinin HA2 domain,

wherein the influenza virus hemagglutinin (HA) stem domain polypeptide domain further comprises one or more modified glycosylation site, wherein the modified glycosylation site comprises a modification of a naturally occurring glycosylation site having an amino acid sequence Asn-Xaa-Ser/Thr/Cys, where the modification disrupts the ability of a glycan to attach to the modified glycosylation site, and wherein Xaa is any amino acid.

71. The influenza virus hemagglutinin (HA) stem domain polypeptide of any one of claims 68 to 71, wherein the modified glycosylation site is located at amino acid positions selected from the group consisting of amino acid positions 20-22, 21-23, 33-35, 46-48, 289-291, 290-292, 296-298 and 481-483, according to the H3 numbering system, wherein the HA stem domain is an HA stem domain from an influenza virus of subtype H1, H2, H5, H6, H8, H9, H11, H12, H13, and H16.

72. The influenza virus hemagglutinin (HA) stem domain polypeptide of any one of claims 68 to 71, wherein the modified glycosylation site is located at amino acid positions selected from the group consisting of amino acid positions 8-10, 22-24, 38-40, 46-48, 296-

298, 410-412, and 481-483, according to the H3 numbering system, wherein the HA stem domain is an HA stem domain from an influenza virus of subtype H3, H4, H7, H10, H14, H15.

73. The HA polypeptide of any one of claims 1-9 or 55-72, wherein said polypeptide is soluble.

74. A nucleic acid encoding the polypeptide of any of claims 55-62.

75. A nucleic acid encoding the polypeptide of any of claims 63-66.

76. A cell expressing the nucleic acid of claim 74.

77. A cell expressing the nucleic acid of claim 75.

78. A virus comprising the chimeric influenza virus hemagglutinin (HA) polypeptide of any one of claims 55-62.

79. A virus comprising the chimeric influenza virus hemagglutinin (HA) polypeptide of any one of claims 63-66.

80. An immunogenic composition comprising the chimeric influenza virus hemagglutinin (HA) polypeptide of any one of claims 55-62.

81. An immunogenic composition comprising the chimeric influenza virus hemagglutinin (HA) polypeptide of any one of claims 63-66.

82. Use of an immunogenic composition of claim 80 in the manufacture of a medicament for immunizing a subject .

83. Use of an immunogenic composition of claim 81 in the manufacture of a medicament for immunizing a subject.

84. The use of claim 82, wherein the subject is human.

85. The use of claim 83, wherein the subject is human.